AMSTERDAM, Netherlands, November 12 /PRNewswire/ --

Eurand N.V. (Nasdaq: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that the Company has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), effective November 19, 2007.

Gearoid Faherty, Chief Executive Officer of Eurand, commented, "We are delighted to be included in this important NASDAQ index and believe it is further validation of our position in the life sciences industry."

The NASDAQ Biotechnology Index includes securities of NASDAQ-listed companies that meet eligibility criteria including market capitalization minimums, trading volume minimums, and ICB classification. The index is ranked on a semi-annual basis in May and November. More information about the NBI is available at www.nasdaq.com

About Eurand

Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand has completed two phase III clinical trials on its lead product candidate, Zentase, for the treatment of Exocrine Pancreatic Insufficiency and filed a rolling NDA for this product which the company anticipates to complete by the end of 2007. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-making/fast-dissolving formulations and drug conjugation.

Eurand is a global company with facilities in the USA and Europe. For more information, visit Eurand's website at www.eurand.com.

This release, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to our plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "potentially", "could", "calls for" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA refuses to approve our NDA; the outcome of any discussions with the FDA; and unexpected delays in preparation of materials for submission to the FDA as a part of our NDA filing. Forward-looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward-looking statements.

Contacts: Mario Crovetto Nick Laudico/Elizabeth Scott Chief Financial Officer The Ruth Group Eurand N.V. +1-646-536-7030/7014 +39-02-95428-521 nlaudico@theruthgroup.com mario.crovetto@eurand.com escott@theruthgroup.com

Web site: http://www.eurand.com

Mario Crovetto, Chief Financial Officer of Eurand N.V., +39-02-95428-521, mario.crovetto@eurand.com; Nick Laudico, +1-646-536-7030, nlaudico@theruthgroup.com, or Elizabeth Scott +1-646-536-7014, escott@theruthgroup.com, both of The Ruth Group, for Eurand N.V.